Clinical Effectiveness of Advanced Hybrid Closed-loop Systems for Achieving Time in Tight Range Among T1D Patients

Launched by CASTILLA-LA MANCHA HEALTH SERVICE · Feb 18, 2025

Keywords

ClinConnect Summary

This clinical trial is studying how well advanced hybrid closed-loop systems help adults with type 1 diabetes (T1D) keep their blood sugar levels within a healthy range. The goal is to see how much time patients can spend with their blood sugar levels between 70 and 140 mg/dL, which is important for preventing long-term health issues related to diabetes. Researchers are looking at three different types of these systems to find out which one works best.

To participate in this study, you need to be at least 18 years old, have type 1 diabetes, and have been using an advanced hybrid closed-loop system for at least three months. You also need to have recent data from your continuous glucose monitor. If you're interested in joining, you should know that the study is currently recruiting participants, and taking part might help improve diabetes management for you and others in the future.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • Patients with type 1 diabetes.
• • Age greater than or equal to 18 years.
• • Treated with advanced hybrid closed-loop systems (AHCL) for at least 3 months
• • Actived continuous glucose monitoring data in the last 14 days.
• Exclusion Criteria:
• • Other types of diabetes.
• • Receiving treatment with insulin regimens other than AHCL.
• • Having received AHCL treatment for less than 3 months in a row prior to inclusion in the study with the same system.
• • No data on use of the AHCL system during the previous 14 days.
• • Severe or uncontrolled psychiatric disorder.
• • Pregnancy or end of pregnancy less than 3 months ago or preparation for pregnancy.